Previous 10 | Next 10 |
Affimed N.V. (AFMD) discloses following passive stake:Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen beneficially own ~5.64M shares, constituting 4.8% stake.Cubist Systematic Strategies and Mr. Cohen beneficially own 177,487 shares, constituting 0.2% stake.Stock ri...
Affimed N.V. (AFMD) has surged ~10.6% in the premarket after announcing that it has entered a research collaboration with Roche (RHHBY) to study its innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).As per t...
Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has entered into a clinical research collaboration with Roche to explore t...
Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its ...
Affimed (AFMD) has priced its public offering of ~16.7M common shares at $6.00/share.Expected net proceeds are ~$94M.Underwriters' over-allotment is an additional 2.5M shares.Closing date is January 15.Shares down 9% premarket.Previously, Jan.12: Affimed N.V. initiates equity offeri...
Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previo...
Gainers: [[MTRX]] +24.8%. [[FARM]] +19.1%. [[STIM]] +15.9%. [[EXFO]] +13.1%. [[FSI]] +11.1%.Losers: [[PRTY]] -12.3%. [[QLI]] -9.2%. [[URBN]] -7.8%. [[PRVB]] -7.4%. [[AFMD]] -5.6%. For further details see: MTRX, FARM, PRTY and QLI among after-hours movers
Affimed N.V. (AFMD) says it has started an underwritten public offering of its common shares, where underwriters will have an overallotment option to purchase up to additional 15% of share offering.Price, size and terms not yet determined.Previously (Jan. 11): Affimed inks €2...
Affimed (AFMD) has entered into a debt financing agreement with Silicon Valley Bank German Branch ((SVB)) which provides Affimed with up to €25M in term loans. “This financing will help support the broad development strategy for our ICE molecules as monotherapies and in com...
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 39th Annual J...
News, Short Squeeze, Breakout and More Instantly...
2024-07-07 08:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 17:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...